Advances in Immunotherapy-NC

Cancer Vaccines

Michael Morse, MD, MHS, FACP Professor of Medicine Duke University Medical Center

Disclosures


 Related Research support: Alphavax, Etubics, Aduro, Precision Biologics, Newlinks, BMS

Overview of lecture

- Background on rationale and biologic mechanism of cancer vaccines
- Tumor antigens
- Vaccine strategies
- Measuring immune responses to Vaccines
- Summary

BACKGROUND ON RATIONALE AND BIOLOGIC MECHANISM OF CANCER VACCINES

Immunotherapy



Vaccine

 (n): medical : a substance that is usually injected into a person or animal to protect against a particular disease

Therapeutic vaccine: Treat an existing disease


http://www.merriam-webster.com/dictionary/vaccine

The first active (nonspecific) immunotherapy?




Coley, William B. "A Preliminary Note on the Treatment of Inoperable Sarcoma by the Toxic Product of Erysipelas." *Post-graduate* 8:278-86, 1893.

Bacillus Calmette–Guérin: Nonspecific immunotherapy




Redelman-Sidi G et al, Nature Reviews Urology, 2014, 11: 153-62.

Problem: Tumors do not have necessary machinery to activate immune system by themselves




Cross presentation of antigen: Goal of vaccines is to direct antigen to dendritic cells




Once activated, T cells can destroy tumor targets without co-stimulatory signals

Tumor Cell



Mechanism of tumor vaccines



TUMOR ANTIGENS

Types of tumor antigens

- Tumor specific
 - Unique to tumor
 - essential for tumorigenesis/ cancer progression
 - caused by somatic mutation
 - not found on any normal adult somatic tissues
 - Personalized

Tumor-associated

appear on various cancer and normal cells, though with different expression levels.

NCI prioritization of cancer antigens

- therapeutic function
- Immunogenicity
- specificity
- oncogenicity
- expression level
- percentage of positive cells
- stem cell expression,
- # of patients with antigen + cancers
- number of epitopes
- cellular location of expression


Examples of Tumor Antigens

- Lymphoma—Id protein
- Melanoma— MAGE antigens, Mart-1, gp 100, tyrosinase
- GI—CEA, *ras,* p53
- Breast—targeting CEA, Her-2/neu, p53
- Prostate PSA, PSA-M
- Lung- CEA, MAGE
- Telomerase
- Endothelial antigens
- Proteins related to resistance mechanisms
- Autologous antigens

Debates regarding tumor antigen


- Defined or undefined antigen
 - Well characterized tumor antigens or use "extracts" from tumor
- If defined: one or multiple antigens
 Role of epitope spreading
- If defined: Class I alone or class I and class II
- If defined: HLA restricted or unrestricted

Challenge to specific immunotherapy: Precursor frequencies are low




VACCINE STRATEGIES

Direct tumor injection: Oncolytic viruses



Woller, Front Oncol. 2014 Jul 21;4:188.

OPTIM Phase III Study Design



Overall Response Rate

ITT Set	GM-CSF (N=141)	T-VEC (N= 295)	Treatment Difference (T-VEC – GM-CSF)
Overall Response Rate (95% CI)	5.7% (1.9, 9.5)	26.4% (21.4, 31.5)	20.8% (14.4, 27.1) P < 0.0001ª descriptive
CR	0.7%	10.8%	
PR	5.0%	15.6%	1

Durable Response Rate (Primary Endpoint)

ITT Set	GM-CSF (N=141)	T-VEC (N= 295)	Treatment Difference (T-VEC - GM-CSF)
Durable Response Rate	2.1%	16.3%	14.1% 95% CI: (8.2, 19.2) P < 0.0001*

ACC


Kaufman ASCO2014; Abst 9008a

Virus	Indication(s)	Phase	Status	Route	Notes	Ref.
CG0070	Bladder carcinoma	I.	n.a.	Intravesical	As a single agent	NCT00109655
ColoAd1	Colorectal carcinoma	I	Recruiting	i.t. or i.v.	As a single agent	NCT02053220
	Ovarian carcinoma	I/II	Not yet recruiting	i.p.	As a single agent	NCT02028117
	Solid tumors	I/II	Recruiting	i.v.	As a single agent	NCT02028442
CVA21	Solid tumors	I.	Not yet recruiting	i.v.	As a single agent	NCT02043665
DNX2401	Glioblastoma	I	Recruiting	i.t.	Combined with temozolomide and/or surgery	NCT01956734
HSV-1716	Glioma	I	Recruiting	Into the tumor resection cavity	Combined with dexamethasone and surgery	NCT02031965
	Melanoma	I	Recruiting	i.v.	As a single agent	NCT01864759
ICOVIR-5	Solid tumors	1/11	Recruiting	i.p. (via MSCs)	As a single agent	NCT01844661
	HNSCC	I	Recruiting	i.t.	As a single agent	NCT01846091
MV-NIS	Ovarian carcinoma	1/11	Not yet recruiting	i.p. (via MSCs)	As a single agent	NCT02068794
Pexa-Vec	Ovarian carcinoma	Ш	Not recruiting	i.v.	As a single agent	NCT02017678
T-vec	Melanoma	Ш	Not yet recruiting	i.t.	As a single agent	NCT02014441
Toca 511	Brain tumors	I	Recruiting	i.v.	Combined with 5-FC	NCT01985256
VCN 01	Pancreatic cancer	I	Recruiting	i.t.	Combined with gemcitabine	NCT02045589
VCN-01	Solid tumors	I	Recruiting	i.v.	Combined with gemcitabine	NCT02045602

Table 1. Clinical trials recently launched to evaluate the safety and efficacy of oncolytic virotherapy in cancer patients*


Pol, Oncolmmunology 3, e28694

Intratumoral injection of immunostimulatory genes




Adapted from Soares, Expert Opin Biol Ther. 2010 May;10(5):841-51.

Tumor cell vaccines: GVAX




Nature Reviews Urology 10, 149-160 (March 2013)


Tumors Transduced with GM-CSF had greatest activity in preclinical models



Dranoff G, et al. Proc Natl Acad Sci USA. 1993;90:3539-3543.



Peptide presented by dendritic cell (APC)



Courtesy: Jeff Schlom, PhD, NCI

Randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients (ASCO 2014;#638)

- Disease-free, node+ or high-risk node- pts; any level of HER2 +; completed adjuvant tx
- AE37 + GM-CSF vs GM-CSF alone
- RRR 12 % in ITT group (19/153 v 20/145 events; HR(CI) 0.89 (0.47, 1.66), p=0.70)
- RRR 40% in HER2 nOE pts (10/76 v 14/78 events; HR(CI) 0.60 (0.26, 1.35), p=0.21)
- RRR 60% in TNBC pts (4/25 v 9/25; HR(CI) 0.40 (0.12, 1.32), p=0.12).

Peptide vaccine development





Fig. 1. Transition of peptide vaccine development for advanced cancer. DC, dendritic cells.

Yamada, Cancer Sci 2013;104:15-21


Anti-Idiotype Vaccines: Inducing antibody and T cell responses



Ladjemi MZ. Front Oncol. 2012 Nov 6;2:158.


Racotumomab-alum: an anti-idiotype vaccine targeting the NeuGcGM3 tumorassociated ganglioside

A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients



Alfonso, Clin Cancer Res. 2014 Jul 15;20(14):3660-71

Heat Shock Proteins



HSP are chaperone proteins


Preps. of HSP (gp96, HSP-70, HSP 90 are noncovalent complex of HSP + peptides

Peptides include normal self and antigenic peptides


HSP bind to CD91 of APCs such as DC and peptide is processed and presented to T cells by MHC class I

Immune resp is individually tumor-specific (i.e. against non-shared Ag)

Viral Vector & Plasmid Vaccines




Viral vector based vaccines



Courtesy Jeff Schlom, NCI

Fowlpox vector (rF-CEA(6D)-TRICOM) vaccine


- Fowlpox infect human cells but cannot replicate
- Do not integrate into the host DNA
- Large capacity; express multiple genes
- Induce minimal anti-vector immune response
- Activate CEA(+) T cells (Marshall, ASCO 2003)



Viral Vector	Advantages	Disadvantages
Mammalian Poxviruses	 Easily manipulated in laboratory setting Accepts large gene inserts 	 Neutralizing antibodies develop with subsequent vaccinations; recipients of vaccinia (smallpox) vaccine
 Vaccinia Virus 	Naturally immunogenic	have pre-existing immunity to vector
(VV)	 Cellular and humoral immune response to transgene 	 Replication-competent virus (VV), not appropriate for
 Modified virus 	 Expresses transgenes in target cells, including DC 	use in immunocompromised patients
Ankara (MVA)	 No risk of insertional mutagenesis 	
	MVA strain is replication-incompetent	
Avian Poxvirus	Incomplete lifecycle in mammalian cells, no infectious viral particles	Immune response is not as robust as vaccinia virus
 Fowlpox 	can form	
 Canarypox 	 Multiple vaccinations possible, no neutralizing antibodies develop 	
(ALVAC)		
Adenovirus (Ad)	 Easily manipulated in laboratory setting Cellular and humoral immune response to transgene High expression of transgene 	 Infection of target cells dependant on express of Ad receptor (e.g. CAR), which is not expressed on all cancer cells
	Broad tropism, including DC	Pre-existing host neutralizing antibodies to several Ad
	No risk of insertional mutagenesis	serotypes
	Many strains available	Limited capacity for gene inserts
	Replication-deficient strains used, limiting pathogenicity	Linned capacity for gene inserts
Alphavirus	Naturally immunogenic	Limited capacity for gene inserts
	High expression of transgene Bertisen commutent vertex	 Limited duration of expression of transgene due to induction of constants in infected toget cell
	Replicon-competent vector	induction of apoptosis in infected target cell
	 No neutralizing antibodies develop against non- propagating vector 	
	Broad tropism	
	 Multiple vaccinations possible, no neutralizing antibodies develop 	


LaRocca, Cancer J. 2011 Sep-Oct;17(5):359-71.

Randomized trial of PSA-TRICOM in prostate cancer




Schlom, Adapted from Kantoff P, J Clin Oncol. 2010;28:1099–1105.

Prime-boost with poxvectors is clinically active



Yeast vectors




Bacterial vector: CRS-207 (Listeria-mesothelin)

LADD Listeria

Live-attenuated Listeria monocytogenes


 Potent activation of innate and antigenspecific immune response




Mesothelin

Le D, GI ASCO 2014


Overall Survival – Full Analysis Set (Planned Interim Analysis, Jan 2013)



Dendritic cell vaccines




Autologous antigen presenting cell for cancer immunotherapy



Dendritic cell vaccine: Sipuleucel-T

Phase III RCT of APC8015 for androgen-independent prostate Ca (*J Clin Oncol 2006;24:3089-3094*)




Most common AE: chills (in 51.2%), fever (22.5%), fatigue (16.0%), nausea (14.2%), headache (10.7%).

Fig 3. Final overall survival (intent-to-treat population). HR, hazard ratio.


OS significantly improved

MEASURING IMMUNE RESPONSES TO VACCINES

Detecting immune response by ELISPOT After Vaccination



Measures of immune response to vaccines Injection site and DTH reactions



JNCI 2004;96:326

Immune response Correlates with

OS




Months from surgery

Fig. 4 Different clinical outcome between immune responders and nonresponders vaccinated with HSPPC-96 after complete liver resection of metastatic CRC. Patients with a postvaccination immune response (17 cases) had a significant survival advantage at 24 months compared with that of nonresponding patients (12 cases) both on OS (A; 100 *versus* 50% at 2 years) and on DFS (B; 51 *versus* 8% at 2 years).

Clin Ca Res 9:3235, 2003

Tumor Growth Rate



Time

Stein W, Gulley JL, et al. Clin Ca Res, 2011

For a therapeutic vaccine to induce an immune response, the following are required except

- A. Cross presentation of antigen by dendritic cells
- B. Antigen unique to tumor
- C. T cells that can recognize the antigen

For a therapeutic vaccine to induce an immune response, the following are required except

- A. Cross presentation of antigen by dendritic cells
- B. Antigen unique to tumor
- C. T cells that can recognize the antigen

Antigens used in vaccines are often normal proteins not unique to tumor, but may be overexpressed or aberrantly expressed

The following statements about viral vector vaccines are true except

- A. Prime-boost vaccination may give stronger immune responses
- B. Viral vectors must directly infect DC to be effective
- C. Viral vectors may contain multiple genes including those to provide multiple activation signals to T cells

The following statements about viral vector vaccines are true except

- A. Prime-boost vaccination may give stronger immune responses
- B. Viral vectors must directly infect DC to be effective
- C. Viral vectors may contain multiple genes including those to provide multiple activation signals to T cells

Due to cross presentation, viral vectors can infect other tissues and still induce immune responses